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harming others and/or themselves. Therefore the importance of
preventing deterioration in a patient’s condition as measured by
PANSS is not only beneﬁcial to the patient but also to society.
Given the difﬁculties in this patient population about maintain-
ing treatment compliance, it may be worthwhile to allocate funds
aimed at reducing symptoms directly or indirectly by improving
compliance.
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OBJECTIVES: Clinical trials have demonstrated the efﬁcacy of
atypical antipsychotic agents in reducing symptoms of schizo-
phrenia. However, the likelihood of sustaining control of schiz-
ophrenic symptoms may depend on treatment persistence. In this
study, we compared treatment persistence between patients who
were initiated on risperidone or olanzapine, the two most widely
prescribed atypical antipsychotic agents. METHODS: We iden-
tiﬁed patients with schizophrenia by ICD-9-CM codes (>1 inpa-
tient or >2 outpatient ICD-9-CM codes >7 days apart) between
July 1, 1998 and June 30, 1999. We further selected those who
were prescribed the target drug during April 1, 1999 through
March 31, 2000 provided that they were not on any antipsy-
chotic agents during the prior six months. Using event history
analysis, we compared treatment persistence in terms of hazard
ratio between olanzapine and risperidone initiators, adjusting for
patient sociodemographic and clinical characteristics. RESULTS:
Following the initiation of the target drug, more patients
switched from risperidone to olanzapine than visa versa. Olan-
zapine initiators had decreased hazards of discontinuation by
14% (unadjusted; p < 0.001) and 12% (adjusted; p = 0.002),
respectively, than risperidone initiators. CONCLUSIONS: Com-
pared with risperidone, olanzapine seems to be better tolerated
by patients as indicated by better treatment persistence. The ini-
tiation of olanzapine may thus increase the likelihood of sus-
taining control of symptoms of schizophrenia. Future research
needs to provide a more comprehensive assessment of treatment
persistence by considering other factors, such as formulary deci-
sion, and other antipsychotic agents in the study and developing
models to assess treatment persistence and switching as two
interdependent competing risks.
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OBJECTIVE: To compare time to ﬁrst psychiatric-related hos-
pitalization and time to ﬁrst medication switch in schizophrenia
patients receiving risperidone long-acting injectable (RLAI) or a
new oral atypical antipsychotic. METHODS: Study sites partic-
ipating in RLAI clinical trials in Canada carried out a retro-
spective chart review of hospitalization and medication use in
schizophrenia patients initiated on RLAI between June 1, 1999
and November 30, 2000. Identical parameters were assessed in
similar patients initiated on a new oral atypical antipsychotic
(control patients) over the same period. RESULTS: Sixty-three
RLAI and 74 control charts were reviewed. Control patients
were signiﬁcantly younger than those in the RLAI group (39.1
years versus 45.3, p = 0.0073) and received risperidone (48.6%),
olanzapine (41.9%) and quetiapine (6.8%) as the oral atypical
antipsychotic. Over the assessment periods, 56.8% of control
patients were hospitalized versus 4.8% of RLAI patients (p <
0.0001). For those patients hospitalized, time to ﬁrst hospital-
ization was marginally but not signiﬁcantly lower for RLAI
patients at 13.8 months compared to 19.3 months for the control
patients, respectively (p = 0.6365). However, control patients
had a signiﬁcantly increased risk of hospitalization, as indicated
by Kaplan Meier survival analysis (p < 0.0001 by log-rank test).
There was no signiﬁcant difference in the number of patients
switching medication (47.6% and 59.5% for RLAI and controls
respectively, p = 0.1742) or in time to ﬁrst medication switch
(39.71 and 34.52 months, log-rank p = 0.2076). However, time
to relapse, deﬁned as a hospitalization or a medication switch,
was signiﬁcantly different (p = 0.0004 by log-rank test) with
50% of controls reaching this endpoint at 18 months versus 60
months for RLAI patients. CONCLUSIONS: This study pro-
vides evidence that RLAI is superior to oral atypicals in reduc-
ing hospitalizations. Furthermore, by virtue of its bi-weekly
administration, RLAI offers atypical therapy without the serious
compliance issues associated with an oral medication, providing
clinical and potential economic advantages.
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OBJECTIVE: To compare psychiatric-related hospitalization
and medication use in patients with schizophrenia, before and
after initiation of risperidone long-acting injectable (RLAI)
therapy. METHODS: Schizophrenia patients who participated in
RLAI clinical trials in Canada were identiﬁed and their charts
were retrospectively reviewed to assess hospitalization and med-
ication use over identical periods before and after the initiation
of RLAI therapy. RESULTS: Sixty-three charts were reviewed.
The mean RLAI treatment period was 40.3 months with 52.4%
of patients still receiving therapy at the time of the chart audit.
The pre- and post-RLAI assessment periods were identical at
39.4 and 40.3 months, respectively (p = 0.8293). There were sta-
tistically signiﬁcant differences in hospitalization before and after
the initiation of RLAI therapy. After initiation of RLAI therapy
fewer patients were hospitalized (52.4% prior to RLAI versus
4.8% during RLAI treatment, Relative Risk = 10.9, p < 0.0001),
fewer patients had more than one hospitalization (24% versus
0%, p < 0.0001), the total duration of hospitalization days
decreased by 99% (1558 versus 23, p < 0.0001), the number of
hospitalizations per patient decreased by 89% (0.9 versus 0.1, 
p < 0.0001) and duration of hospitalization decreased by 98%
(24.7 days per patient versus 0.4, p < 0.0001). Furthermore, anti-
cholinergic and anxiolytic use decreased from 81% of patients
to 64% (p = 0.0459) and 57% to 35% (0.0198), respectively,
with RLAI while sedative use was not signiﬁcantly different
(22% and 16% of patients used sedatives pre- and post-RLAI,
respectively, p = 0.4967). CONCLUSIONS: RLAI had a signiﬁ-
cant impact on hospitalization of schizophrenia patients, offer-
ing a clear clinical beneﬁt compared to traditional antipsychotic
therapy. In addition, the signiﬁcant decrease in hospitalization
